Vivasc Therapeutics is a drug development company that specializes in proprietary cardiac targeting peptide platform technology.
Vivasc Therapeutics has raised $284K in total funding. The most recent round was Grant. The last funding was announced in October 2022.
Vivasc Therapeutics's investors include National Heart, Lung and Blood Institute.
Vivasc Therapeutics is headquartered in Pittsburgh, United States.
Vivasc Therapeutics is a drug development company that specializes in proprietary cardiac targeting peptide platform technology.
Vivasc Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vivasc Therapeutics — Funding & Investors." VCBacked, October 19, 2022, https://www.vcbacked.co/company/vivasc-therapeutics. Accessed August 14, 2026.
VCBacked. (2022). Vivasc Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/vivasc-therapeutics
{{cite web |title=Vivasc Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/vivasc-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated